Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine

Brain Research

Volumn 1335, Issue , 2010, Pages 24-34

  Freo, Ulderico ^a   Merico, Antonio ^b   Ermani, Mario ^a   Ori, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ospedale/IRCCS   (Italy)

Author keywords

1 (2,5 dimethoxy 4 iodophenyl) 2 aminopropane; 8 hydroxy 2(di N propylamino)tetralin; Apomorphine; Cerebral metabolism; Fluoxetine; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; APOMORPHINE; AUTORECEPTOR; CARBON 14; DEOXYGLUCOSE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUOXETINE; GLUCOSE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BRAIN METABOLISM; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MECHANISM; GLUCOSE METABOLISM; HEAD MOVEMENT; LIMBIC SYSTEM; LOCOMOTION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; SEROTONIN SYNDROME;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMPHETAMINES; ANIMALS; APOMORPHINE; BRAIN; DOPAMINE AGONISTS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; MALE; RATS; RATS, INBRED F344; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; UP-REGULATION;

RATTUS;

EID: 77952321608     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.03.090     Document Type: Article

References (57)

1. Ainsworth K., Smith S.E., Zetterström T.S., Pei Q., Franklin M., and Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology 140 (1998) 470-477
2. Alex K.D., and Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113 (2007) 296-320
3. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31 (1996) 444-469
4. Bedard P., and Pycock C.J. "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology 16 (1977) 663-670
5. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., and Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100, 907. Am. J. Psychiatry 163 (2006) 1580-1587
6. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
7. Bortolozzi A., Díaz-Mataix L., Scorza M.C., Celada P., and Antigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 95 (2005) 1597-1607
8. Bymaster F.P., Zhang W., Carter P.A., Shaw J., Chernet E., Phebus L., Wong D.T., and Perry K.W. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology 160 (2002) 353-361
9. Cadogan A.K., Marsden C.A., Tulloch I., and Kendall D.A. Evidence that chronic administration of paroxetine or fluoxetine enhances 5-HT2 receptor function in the brain of the guinea pig. Neuropharmacology 32 (1993) 249-256
10. Caley C.F. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann. Pharmacother. 31 (1997) 1481-1489
11. Chaput Y., de Montigny C., and Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5 (1991) 219-229
12. Dam M., Tonin P., De Boni A., Pizzolato G., Casson S., Ermani M., Freo U., Piron L., and Battistin L. The effects of fluoxetine and maprotiline on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27 (1996) 1211-1214
13. Damjanoska K.J., Van de Kar L.D., Kindel G.H., Zhang Y., D'Souza D.N., Garcia F., Battaglia G., and Muma N.A. Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus. J. Pharmacol. Exp. Ther. 306 (2003) 563-571
14. Dell'Agnello G., Ceravolo R., Nuti A., Bellini G., Piccinni A., D'Avino C., Dell'Osso L., and Bonuccelli U. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin. Neuropharmacol. 24 (2001) 221-227
15. Dziedzicka-Wasylewska M., Dlaboga D., Pierzchała-Koziec K., and Rogóz Z. Effect of tianeptine and fluoxetine on the levels of Met-enkephalin and mRNA encoding proenkephalin in the rat. J. Physiol. Pharmacol. 53 (2002) 117-125
16. Freo U. Cerebral metabolic effects of serotonin drugs and neurotoxins. A minireview. Life Sci. 59 (1996) 877-891
17. Freo U., Soncrant T.T., Holloway H.W., and Rapoport S.I. Dose- and time-dependent effects of 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonergic 5-HT2 receptor agonist, on local cerebral glucose metabolism in awake rats. Brain Res. 541 (1991) 63-69
18. Freo U., Ori C., Weiss S.R., and Perini G.I. Time- and dose-dependent effects of corticotropin releasing factor on cerebral glucose metabolism in rats. J. Neural Transm. 112 (2005) 1447-1462
19. Goodwin G.M., and Green A.R. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br. J. Pharmacol. 84 (1985) 743-753
20. Grasby P.M., Sharp T., Kelly P., and Grahame-Smith D.G. Dose related effects of the 5-HT1A agonist 8-OH-DPAT on glucose utilization in rat brain studied with 2-DG autoradiography. Soc. Neurosci. Abstr. 15 (1989) 421
21. Hensler J.G. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 (2002) 565-573
22. Hrdina P., and Vu T.B. Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse 14 (1993) 324-331
23. Izumi T., Suzuki K., Inoue T., Li X.B., Maki Y., Muraki I., Kitaichi Y., Hashimoto S., and Koyama T. Long-lasting change in 5-HT2A receptor-mediated behavior in rats after a single footshock. Eur. J. Pharmacol. 452 (2002) 199-204
24. Jacobs B.L., and Klemfuss H. Brainstem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Res. 100 (1975) 450-457
25. Kelly P.A.T., Davis C.J., and Goodwin G.M. Differential patterns of local cerebral glucose utilization in response to 5-hydrotryptamine1 agonists. Neuroscience 25 (1988) 907-915
26. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., and Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27 (2002) 949-959
27. Kreiss D.S., and Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274 (1995) 866-876
28. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog. Neuropsychopharmacol. Biol. Psychiatry 12 (1988) 117-164
29. Lammers C.H., Diaz J., Schwartz J.C., and Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry 5 (2000) 378-388
30. Le Poul E., Boni C., Hanoun N., Laporte A.M., Laaris N., Chaveau J., Hamon M., and Lanfumey L. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39 (2000) 110-122
31. Leon A.L., and Cardenas F.P. Contribution of the dopaminergic system to the effect of chronic fluoxetine in the rat forced swim test. Psychol. Neurosci. 1 (2008) 81-89
32. Li Q., Levy A.D., Cabrera T.M., Browfield T.S., Battaglia G., and Van de Kar L.D. Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to 5-HT1A agonist, 8-OH-DPAT, in male rats. Brain Res. 630 (1993) 148-156
33. Li Q., Brownfield M.S., Levy A.D., Battaglia G., Cabrera T.M., and Van de Kar L.D. Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biol. Psychiatry 36 (1994) 300-308
34. Lucki I., and Minugh-Purvis N. Serotonin-induced head shaking behavior in rats does not involve receptors located in the frontal cortex. Brain Res. 420 (1987) 403-406
35. Maj J., and Moryl E. Effects of fluoxetine given chronically on the responsiveness of 5-HT receptors subpopulations to their agonists. Eur. Neuropsychopharmacol. 3 (1993) 85-94
36. Maj J., Dziedzicka-Wasylewska M., Rogoz R., Rogóz Z., and Skuza G. Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. Eur. J. Pharmacol. 304 (1996) 49-54
37. Massou J.M., Trichard C., Attar-Levy D., Feline A., Corruble E., Beaufils B., and Martinot J.L. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology 133 (1997) 99-101
38. Messa C., Colombo C., Moresco R.M., Gobbo C., Galli L., Lucignani G., Gilardi M.C., Rizzo G., Smeraldi E., Zanardi R., Antigas F., and Fazio F. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology 167 (2003) 72-78
39. Mintun M.A., Sheline Y.I., Moerlein S.M., Vlassenko A.G., Huang Y., and Snyder A.Z. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol. Psychiatry 55 (2004) 217-224
40. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 67 Suppl 6 (2006) 3-8
41. Orzi F., Morelli M., Fieschi C., and Pontieri F.E. Metabolic mapping of the pharmacological and toxicological effects of dopaminergic drugs in experimental animals. Cerebrovasc. Brain Metab. Rev. 5 (1993) 95-121
42. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., Van Heertum R.L., Arango V., and Mann J.J. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry 59 (2006) 106-113
43. Pehek E.A., McFarlane H.G., Maguschak K., Price B., and Pluto C.P. M100, 907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 888 (2001) 51-59
44. Rapoport S.I., Basselin M., Kim H.W., and Rao J.S. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res. Rev. 61 (2009) 185-209
45. Sekine Y., Suzuki K., Ramachandran P.V., Blackburn T.P., and Ashby Jr. C.R. Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 61 (2007) 72-77
46. Sheehan T.P., Chambers R.A., and Russell D.S. Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res. Rev. 46 (2004) 71-117
47. 14C]-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal value in the conscious and anesthetized albino rat. J. Neurochem. 28 (1985) 897-916
48. Soncrant T.T., Pizzolato G., and Battistin L. The use of drugs as probes of cerebral function. In: Battistin L., and Gerstenbrand F. (Eds). PET and NMR: new perspectives in neuroimaging and in clinical neurochemistry (1985), Liss, New York 131-149
49. Sprouse J.S., and Aghajanian G.K. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27 (1988) 707-715
50. Swerdlow N.R., Vaccarino F.J., Amalric M., and Koob G.F. The neural substrates for the motor-activating properties of psychostimulans: a review of recent findings. Pharmacol. Biochem. Behav. 25 (1986) 233-248
51. Tilakaratne N., Yang Z., and Friedman E. Chronic fluoxetine or desmethylimipramine treatment alters 5-HT2 receptor mediated c-fos gene expression. Eur. J. Pharmacol. 290 (1995) 263-266
52. Tohda M., Nomura M., and Nomura Y. Molecular pathopharmacology of 5-HT2C receptors and the RNA editing in the brain. J. Pharmacol. Sci. 100 (2006) 427-432
53. Tyeryar K.R., Vongtau H.O., and Undieh A.S. Diverse antidepressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain. BMC Neurosci. 24 (2008) 9-12
54. Van Oekelen D., Luyten W.H., and Leysen J.E. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 72 (2003) 2429-2449
55. van Wijngaarden I., Tulp M.T., and Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188 (1990) 301-312
56. Welner S.A., De Montigny C., Desroches J., Desjardins P., and Suranyi-Cadotte B.E. Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment. Synapse 4 (1989) 347-352
57. Willins D.L., and Meltzer H.Y. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282 (1997) 699-706